Baxter International

Baxter to Present at Bank of America 2024 Health Care Conference

Retrieved on: 
Martedì, Maggio 7, 2024
Professional Services, Medical Supplies, Health, Other Health, Finance, General Health, Banking, Hospital, Baxter International, Nursing care plan, Patient, Bank, Conference, Medtech, Caregiver

Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America 2024 Health Care Conference on Wednesday, May 15, 2024.
  • Joel Grade, Baxter’s chief financial officer, is scheduled to present at 3:00 p.m. Pacific Time.
  • The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Wednesday, August 14, 2024.
  • Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care.

Diality Welcomes Ravi Parthasarathy as Chief Technology Officer

Retrieved on: 
Martedì, Maggio 7, 2024
Medical Devices, Health, Kidney disease, Motorola, Moda, Research, Baxter International, ICU Medical, General Motors, Patient, CSO, Inc., Quality of life, Management

Diality Inc. , a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.

Key Points: 
  • Diality Inc. , a medical device company developing the Moda-flxTM Hemodialysis System, today announced that Ravi Parthasarathy has joined the company as Chief Technology Officer.
  • Parthasarathy comes to Diality with decades of product development team leadership experience, most recently with ICU Medical, where he served as Vice President, Device Engineering.
  • Prior to ICU Medical, he served in leadership and product development roles for Baxter Healthcare, Motorola, Siemens Medical Systems, and General Motors.
  • “We are delighted to welcome someone of Ravi’s expertise and passion to Diality,” said Osman Khawar, M.D., CEO of Diality.

Baxter Declares Quarterly Dividend

Retrieved on: 
Martedì, Maggio 7, 2024
Medical Supplies, Health, Medical Devices, Health Technology, Pharmaceutical, Optical, Biotechnology, Baxter International

Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock.
  • The dividend is payable on July 1, 2024, to stockholders of record as of May 31, 2024.
  • The indicated annual dividend rate is $1.16 per share of common stock.

Alcyone Therapeutics Announces Appointment of Dr. Norbert Riedel as Chairman of the Board and Dr. Kathrin Meyer as Chief Scientific Officer and Head of Research & Development

Retrieved on: 
Mercoledì, Maggio 8, 2024
Doctor of Philosophy, University, MicroRNA, Gene therapy, Hospital, Central nervous system disease, Rett syndrome, Innovation, Jazz Pharmaceuticals, Research, Ohio State University, History, CNS, Baxter International, Therapy, Batten disease, Patient, Acquisition, Gene expression, Nationwide Children's Hospital, Central nervous system, Health, SMARD1, Growth, Medical device

LOWELL, Mass., May 8, 2024 /PRNewswire/ -- Alcyone Therapeutics, a clinical-stage biotechnology company pioneering next-generation precision genetic therapies for complex neurological conditions, today announces appointments of Norbert Riedel, Ph.D., a skilled and experienced biopharmaceutical executive, as the Chairman of its Board of Directors, and Kathrin Meyer, Ph.D., a leader in development and clinical translation of genetic therapies for the central nervous system (CNS), as Alcyone's new Chief Scientific Officer and Head of R&D.

Key Points: 
  • "I am delighted and honored to join the board of Alcyone Therapeutics," said Dr. Riedel.
  • I am very excited about the programs we have in development to address the significant unmet patient needs in several neurological indications."
  • "Developing neurological genetic therapies demands both a highly precise biological mechanism of action and effective delivery to the central nervous system.
  • Dr. Kathrin Meyer is a pioneer in the research and clinical development of novel therapies for the CNS.

Cardiac Monitoring & Cardiac Rhythm Management Devices Market Worth $26.4 billion | MarketsandMarkets™

Retrieved on: 
Giovedì, Maggio 2, 2024
USD, MicroPort, FDA, Asahi Kasei, Investment, GE HealthCare, Laboratory, Risk, Hospital, Monitor lizard, Biomedical Research, Research, ECG, Abbott Laboratories, Baxter International, ICM, Patient, Boston Scientific, Acquisition, Arrhythmia, Cardiology, Diagnosis, Biotechnology, Market development, Medical device

Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.

Key Points: 
  • Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.
  • Cardiac Monitoring & Cardiac Rhythm Management Devices Market Dynamics:
    Key Market Players of Cardiac Monitoring & Cardiac Rhythm Management Devices Industry:
    The major players in the cardiac monitoring & cardiac rhythm management devices Market are Abbott Laboratories (US), Medtronic (Ireland), Boston Scientific Corporation (US), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation.
  • {deal size USD 12.5 billion}
    Cardiac Monitoring & Cardiac Rhythm Management Devices Market - Key Benefits of Buying the Report:
    This report studies the cardiac monitoring & cardiac rhythm management devices market based on Type, Application, Procedure, End User, and Region.
  • Market Penetration: Comprehensive information on cardiac monitoring & cardiac rhythm management devices Market products offered by the top 25 players in the market.

Cardiac Monitoring & Cardiac Rhythm Management Devices Market Worth $26.4 billion | MarketsandMarkets™

Retrieved on: 
Giovedì, Maggio 2, 2024
USD, MicroPort, FDA, Asahi Kasei, Investment, GE HealthCare, Laboratory, Risk, Hospital, Monitor lizard, Biomedical Research, Research, ECG, Abbott Laboratories, Baxter International, ICM, Patient, Boston Scientific, Acquisition, Arrhythmia, Cardiology, Diagnosis, Biotechnology, Market development, Medical device

Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.

Key Points: 
  • Based on the North America region, the cardiac monitoring & cardiac rhythm management devices Market is divided into US and Canada.
  • Cardiac Monitoring & Cardiac Rhythm Management Devices Market Dynamics:
    Key Market Players of Cardiac Monitoring & Cardiac Rhythm Management Devices Industry:
    The major players in the cardiac monitoring & cardiac rhythm management devices Market are Abbott Laboratories (US), Medtronic (Ireland), Boston Scientific Corporation (US), GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation.
  • {deal size USD 12.5 billion}
    Cardiac Monitoring & Cardiac Rhythm Management Devices Market - Key Benefits of Buying the Report:
    This report studies the cardiac monitoring & cardiac rhythm management devices market based on Type, Application, Procedure, End User, and Region.
  • Market Penetration: Comprehensive information on cardiac monitoring & cardiac rhythm management devices Market products offered by the top 25 players in the market.

bioAffinity Technologies News Update

Retrieved on: 
Giovedì, Maggio 2, 2024
Research, Medical Devices, Health Technology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Physician, Nursing care plan, ATS, Chronic obstructive pulmonary disease, Lung cancer, Bronchoalveolar lavage, Conference, Baxter International, BIAF, Lung, Patient, Pulmonology, Marketing, Empathy, BAL, American Thoracic Society, Fluid, COPD, Pharmaceutical industry

bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.

Key Points: 
  • bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW) shares recent Company news.
  • Physicians outside of Texas are also signing up with our wholly owned subsidiary, Precision Pathology Laboratory Services, to order CyPath® Lung for their patients.
  • bioAffinity Technologies’ National Sales Director Dallas Coleman announced that Jackie Kennedy has joined the Company as Pulmonary Sales Executive for CyPath® Lung in the San Antonio/Austin market.
  • “Patients have told us how much they appreciate having a Patient Coach who can walk them through the collection process,” bioAffinity Technologies President and CEO Maria Zannes said.

Baxter Reports First-Quarter 2024 Results

Retrieved on: 
Giovedì, Maggio 2, 2024
Medical Supplies, Medical Devices, Health, Pharmaceutical, Optical, Biotechnology, Sale, FDA, Baxter, Pharmacist, Sodium chloride, Food, Growth, LVP, SYR, Novum, Baxter International, Nursing, Patient, EPS, CDT, BPS, GAAP, Food and Drug Administration, Vasopressin

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2024.
  • Regardless of the selected path, Baxter currently expects the separation of its Kidney Care business to take place in the second half of 2024.
  • For full-year 2024: Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis.
  • A webcast of Baxter’s first-quarter 2024 conference call for investors can be accessed live from a link in the Investor Relations section of the company’s website at www.baxter.com beginning at 7:30 a.m. CDT on May 2, 2024.

Exergen Sues Baxter International to Defend Its Right to Publish Data Regarding the Accuracy of Oral Thermometers

Retrieved on: 
Mercoledì, Aprile 24, 2024
General Health, Medical Devices, Hospitals, Health, Health Technology, Speech, Baxter International, Exergen Corporation, District court

Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts.

Key Points: 
  • Last week Exergen Corporation filed a lawsuit against Baxter International Inc. in the United States District Court for the District of Massachusetts.
  • As detailed in its complaint, Exergen’s lawsuit is a response to an effort by Baxter to censor true statements that Exergen has made in a scientific journal about a matter of public concern, among other issues.
  • Through its lawsuit, Exergen seeks a legal declaration that its statements are not only true, but that they constitute First Amendment protected speech.
  • Exergen looks forward to having this matter resolved in a court of law.

Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

Retrieved on: 
Martedì, Aprile 23, 2024
Research, Engineering, Manufacturing, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, APTX, AbbVie, MD, CNS, Baxter International, Boston Consulting Group, Patient, Management

Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.

Key Points: 
  • Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer.
  • Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience.
  • He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company.
  • “We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company,” said Tentarix Chairman Donald Santel.